Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745080 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 853
- Enrollment target
NCT02745080 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 853 participants.
The verdict
NCT02745080, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 853 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).
Interventions
- BIOLOGICAL Adalimumab
- BIOLOGICAL Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 853 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02745080
The ClinicalTrials.gov registry entry for NCT02745080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 853 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT02745080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02745080 about?
NCT02745080 is a clinical study titled "Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis". This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate respon...
What is the current status of trial NCT02745080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 853 participants. The study started on 2017-04-03. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT02745080?
The interventions under investigation include: Adalimumab (BIOLOGICAL), Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02745080?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.